Literature DB >> 34850185

Associations Between Nicotine Knowledge and Smoking Cessation Behaviors Among US Adults Who Smoke.

L M Snell1, S M Colby1, T DeAtley1, R Cassidy1, J W Tidey1.   

Abstract

INTRODUCTION: Misperceptions about nicotine's contribution to smoking-related health harms could complicate efforts to reduce the public health burden of smoking. Study goals were to describe nicotine knowledge among adults who smoke and investigate whether misperceiving nicotine as a source of health harm was associated with beneficial health behaviors, or lower uptake of using less harmful sources of nicotine to support smoking cessation attempts.
METHOD: This study used longitudinal data from 9140 adults who participated in four waves of the Population Assessment of Tobacco and Health Study and were current smokers during the first wave. Logistic regressions estimated odds ratios for correct responses across six aspects of nicotine knowledge assessed in Wave 4. Longitudinal models estimated associations between misperceptions and cigarette consumption, and odds of making a quit attempt; self-reported cessation; e-cigarette use; and use of NRT or e-cigarettes to support quit attempts.
RESULTS: Participants who were non-White, older, and had lower educational attainment or income tended to be least knowledgeable about nicotine. Misperceiving nicotine as harmful to health was associated with increased odds of quit attempts (AOR: 1.12, 95% CI: 1.03, 1.23), lower odds of cessation success (AOR: 0.84, 95% CI: 0.73, 0.98) and e-cigarette use (AOR: 0.79, 95% CI: 0.72, 0.86), and lower odds of using NRT (AOR: 0.84, 95% CI: 0.71, 0.99) or e-cigarettes to support quit attempts (AOR: 0.59, 95% CI: 0.49, 0.71).
CONCLUSION: Harm reduction efforts may be impeded by misperceptions about nicotine. Further work should evaluate the effects of correcting such misperceptions through public education. IMPLICATIONS: This study provides longitudinal evidence that among adult smokers, misperceiving nicotine as a primary cause of smoking-related diseases may be associated with reduced cessation success and lower likelihood of using less harmful nicotine products. These misperceptions may therefore impede efforts to encourage smokers ready to quit to use evidence-based cessation support such as nicotine replacement during quit attempts and limit the success of policies designed to shift smokers to less harmful sources of nicotine. Further work should evaluate the longitudinal effects of correcting nicotine misperceptions through public education targeted toward adults who smoke.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34850185      PMCID: PMC9048939          DOI: 10.1093/ntr/ntab246

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   5.825


  36 in total

1.  Cronbach's alpha.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1997-02-22

2.  Withholding differential risk information on legal consumer nicotine/tobacco products: The public health ethics of health information quarantines.

Authors:  Lynn T Kozlowski; David Sweanor
Journal:  Int J Drug Policy       Date:  2016-04-01

3.  Harm Minimization and Tobacco Control: Reframing Societal Views of Nicotine Use to Rapidly Save Lives.

Authors:  David B Abrams; Allison M Glasser; Jennifer L Pearson; Andrea C Villanti; Lauren K Collins; Raymond S Niaura
Journal:  Annu Rev Public Health       Date:  2018-01-11       Impact factor: 21.981

4.  Current Cigarette Smoking Among Adults - United States, 2005-2015.

Authors:  Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-11       Impact factor: 17.586

5.  Harm perception among Swedish daily smokers regarding nicotine, NRT-products and Swedish Snus.

Authors:  Tom Wikmans; Lars Ramström
Journal:  Tob Induc Dis       Date:  2010-08-13       Impact factor: 2.600

6.  Design and methods of the Population Assessment of Tobacco and Health (PATH) Study.

Authors:  Andrew Hyland; Bridget K Ambrose; Kevin P Conway; Nicolette Borek; Elizabeth Lambert; Charles Carusi; Kristie Taylor; Scott Crosse; Geoffrey T Fong; K Michael Cummings; David Abrams; John P Pierce; James Sargent; Karen Messer; Maansi Bansal-Travers; Ray Niaura; Donna Vallone; David Hammond; Nahla Hilmi; Jonathan Kwan; Andrea Piesse; Graham Kalton; Sharon Lohr; Nick Pharris-Ciurej; Victoria Castleman; Victoria R Green; Greta Tessman; Annette Kaufman; Charles Lawrence; Dana M van Bemmel; Heather L Kimmel; Ben Blount; Ling Yang; Barbara O'Brien; Cindy Tworek; Derek Alberding; Lynn C Hull; Yu-Ching Cheng; David Maklan; Cathy L Backinger; Wilson M Compton
Journal:  Tob Control       Date:  2016-08-08       Impact factor: 7.552

7.  A Longitudinal Analysis of Nicotine Dependence and Transitions From Dual Use of Cigarettes and Electronic Cigarettes: Evidence From Waves 1-3 of the PATH Study.

Authors:  L Morgan Snell; Andrew J Barnes; Nicole E Nicksic
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

8.  Psychological distress and responses to comparative risk messages about electronic and combusted cigarettes.

Authors:  Bo Yang; Claire Adams Spears; Lucy Popova
Journal:  Addict Behav       Date:  2018-11-19       Impact factor: 4.591

9.  Demographic Characteristics, Cigarette Smoking, and e-Cigarette Use Among US Adults.

Authors:  Margaret Mayer; Carolyn Reyes-Guzman; Rachel Grana; Kelvin Choi; Neal D Freedman
Journal:  JAMA Netw Open       Date:  2020-10-01

10.  A longitudinal assessment of nicotine dependence, mental health, and attempts to quit Smoking: Evidence from waves 1-4 of the Population Assessment of Tobacco and Health (PATH) study.

Authors:  Morgan Snell; David Harless; Sunny Shin; Peter Cunningham; Andrew Barnes
Journal:  Addict Behav       Date:  2020-12-16       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.